gefitinib has been researched along with glutamic acid in 3 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (glutamic acid) | Trials (glutamic acid) | Recent Studies (post-2010) (glutamic acid) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 41,757 | 452 | 12,876 |
Protein | Taxonomy | gefitinib (IC50) | glutamic acid (IC50) |
---|---|---|---|
Chain A, GLUTAMATE RECEPTOR SUBUNIT 2 | Rattus norvegicus (Norway rat) | 0.821 | |
Chain A, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.821 | |
Chain B, Glutamate Receptor Subunit 2 | Rattus norvegicus (Norway rat) | 0.821 | |
Metabotropic glutamate receptor 8 | Homo sapiens (human) | 0.0057 | |
Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | 0.07 | |
Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | 0.07 | |
Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.5885 | |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.5885 | |
Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.5885 | |
Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.5885 | |
Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | 0.38 | |
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.1533 | |
Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | 0.38 | |
Glutamate receptor 1 | Homo sapiens (human) | 0.613 | |
Glutamate receptor 2 | Homo sapiens (human) | 0.613 | |
Glutamate receptor 3 | Homo sapiens (human) | 0.613 | |
Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | 0.38 | |
Excitatory amino acid transporter 1 | Homo sapiens (human) | 207 | |
Glutamate receptor 4 | Homo sapiens (human) | 0.613 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.1533 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.1533 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.1533 | |
Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | 0.38 | |
Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 0.07 | |
Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 0.07 | |
Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 0.07 | |
Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | 0.07 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.1533 | |
Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | 0.38 | |
Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | 0.07 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.1533 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.1533 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H | 1 |
Carrillo, V; Dubisz, E; Gulzar, H; Mahajan, SS; Morgan, D; Yelskaya, Z | 1 |
1 trial(s) available for gefitinib and glutamic acid
Article | Year |
---|---|
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Glutamic Acid; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Quinazolines; Treatment Outcome | 2006 |
2 other study(ies) available for gefitinib and glutamic acid
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.
Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Glioblastoma; Glutamic Acid; Humans; Quinazolines; Riluzole; Xanthenes | 2013 |